Inhibition of Aspartate β-Hydroxylase Enhances Anti-Tumor Immunity

původní článek
Creative Commons License IconCreative Commons BY Icon
Thumbnail
File can be accessed.Získat publikaci
Autor
Johari, Shweta DilipORCiD Profile - 0000-0001-6265-8949WoS Profile - ILO-5336-2023Scopus Profile - 57222993686
Krausová, KateřinaORCiD Profile - 0009-0002-4812-8380WoS Profile - DAO-3282-2022Scopus Profile - 7801502020
Žucha, BarboraORCiD Profile - 0009-0004-9398-7381WoS Profile - CLJ-4905-2022Scopus Profile - 57351757500
Madureira Trufen, Carlos Eduardo
Poláková, IngridORCiD Profile - 0000-0003-1315-0924WoS Profile - I-9355-2014Scopus Profile - 24766742200
Olsen, Mark
Šmahel, MichalORCiD Profile - 0000-0002-0366-4932WoS Profile - H-4317-2017Scopus Profile - 6701604039

Datum vydání
2025
Publikováno v
ImmunoTargets and Therapy
Ročník / Číslo vydání
14 (July)
ISBN / ISSN
ISSN: 2253-1556
ISBN / ISSN
eISSN: 2253-1556
Metadata
Zobrazit celý záznam
Kolekce
Abstrakt
Aspartate β-hydroxylase (ASPH) contributes to carcinogenesis by promoting tumor cell proliferation, migration, and invasion. The enzymatic activity of ASPH can be inhibited by small molecule inhibitors that have been shown to have antimetastatic activity in rodent models. ASPH has also been shown to inhibit the activation of natural killer (NK) cells. Therefore, this study aimed to investigate the effect of ASPH inhibition on the induction of anti-tumor immunity and to analyze the immune cells involved.
Klíčová slova
cancer immunotherapy, ASPH, adaptive immunity, scRNA-seq, tumor microenvironment
Trvalý odkaz
https://hdl.handle.net/20.500.14178/3141
Zobraz publikaci v dalších systémech
WOS:001526770200001
PUBMED:40655119
Licence

Licence pro užití plného textu výsledku: Creative Commons Uveďte původ 4.0 International

Zobrazit podmínky licence